We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Lloyds Banking Group Plc | LSE:LLOY | London | Ordinary Share | GB0008706128 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.08 | -0.16% | 50.92 | 50.86 | 50.90 | 51.08 | 50.20 | 50.70 | 115,482,629 | 16:35:22 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Commercial Banks, Nec | 23.74B | 5.46B | 0.0859 | 5.92 | 32.33B |
Date | Subject | Author | Discuss |
---|---|---|---|
24/5/2021 13:03 | POsullivan, on Yellowstone. I must look very American because whenever I go to Yellowstone everyone talks to me in English. | utrickytrees | |
24/5/2021 12:53 | If anyone here is attending the Yellowstone presentation from LLOY at 2pm today it would be nice to hear your thoughts. It would also make for a pleasant diversion from some of the unhinged political, ahem, commentary that spams this board. | pdosullivan | |
24/5/2021 12:49 | They're addicted to crystal meth Scruff, a couple of rocks in your tea in the morning & you'd pop a cap in someone's ass. | utrickytrees | |
24/5/2021 12:47 | Lots of guns owned in the US by white rednecks. | minerve 2 | |
24/5/2021 12:22 | Got my test and trace kit. Quite neat and well designed, must cost a bob or two, and probably several tens of millions required, very profitable for someone i would think. Made in China of course. Slightly better than made in Hamburg I suppose, but why not made in Bradford or Pratts Bottom? | pierre oreilly | |
24/5/2021 12:21 | Cummings is going to spew the truth soon. Knowing him as the data freak he is going to have all the evidence he needs. | minerve 2 | |
24/5/2021 12:19 | Keyboard warriors and armchair generals, you can't beat them. ;) | minerve 2 | |
24/5/2021 12:09 | ROFLMAO what a proper clown Remember him saying that Brexit would be reversed by the next government!!c LOLOLOL. | sentimental rules | |
24/5/2021 11:49 | Dr Biotech is still in denial about "Ivermectin" Interestingly update from India The Times of India published an editorial this week signed by Dr. Vikas Sukhatme and Vidula Sukhatme, two American academics and medical professionals, suggesting a handful of cheap, commonplace drugs that could be taken as prophylactics by the most vulnerable patients in India. The drugs aren't approved to treat COVID, but nevertheless have shown "remarkable promise in preventing or treating the new coronavirus." Deploying them would likely reduce mortality and hospitalizations. While some of the drugs are currently being tested in large-scale randomized trials, there's no time to wait for the outcome. Instead, Indian health authorities should issue guidelines recommending use of the most promising drugs for each stage of COVID-19. By so doing, physicians will be encouraged to prescribe them as interventions. The resulting data should of course be tracked for any insights it might show. The two main drugs cited by the doctors, ivermectin and fluvoxamine, have proven effective, and anecdotal unpublished data from more than 400 acutely ill COVID-19 patients suggests that prescribing fluvoxamine and ivermectin together may be even more efficacious. While daily case numbers have retreated from the peak in India, hospitalizations and mortality remain near all-time highs. Of course, as developing nations fight to waive IP protections for COVID vaccines, the notion that cheap existing drugs might be effective at combating COVID would represent yet another threat to Big Pharma's bottom line. | geckotheglorious | |
24/5/2021 11:47 | If stupidity was a commodity morons like you would be rich. | madd_rip | |
24/5/2021 11:46 | Gecko these mindlessly angry remainiacs are quite a sad but hilarious bunch great to see the hate frothing from their pathetic little mouths | sentimental rules |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions